# How to license a technology from AIIMS and other medical institutes

URL: https://zernyxhub.com/blog/license-technology-from-aiims
Author: Sahil Sheikh, Regd. Patent & Trademark Agent, cRTTP
Published: 2026-11-07
Category: Licensing

> AIIMS technology transfer explained: who owns the IP, the IPR and TT Division, the 2017 IPR policy, how to approach AIIMS and what to check before signing.

**Short answer:** AIIMS New Delhi licenses inventions made by its faculty and staff through its Intellectual Property Rights and Technology Transfer Division, under the AIIMS IPR Policy 2017. AIIMS owns IP created with its resources. Each agreement sets its own fee and royalty. After direct costs are recovered, inventors get 70% of income and the institute 30%.

Doctors at India's medical institutes see unmet needs every day, and many of them turn those needs into devices, diagnostics, software and methods. The All India Institute of Medical Sciences (AIIMS), New Delhi, has an IP policy, a technology transfer division and an incubator. For a company, that means there is a defined route to license what its clinicians invent.

Compared with an engineering institute, the route is less visible. AIIMS does not publish a long catalogue of technologies for licence, so most deals start with a conversation. This guide covers how the AIIMS IPR Policy 2017 shapes a licence, who to approach, what a deal looks like, the regulatory work that follows and how other medical institutes differ.

## Who owns the IP, and who signs?

The [AIIMS IPR Policy 2017](https://www.aiims.edu/aiims/departments_17_5_16/IPR/01-IPR%20policy%202017-for%20upload.pdf), implemented from 16 December 2017, sets out the basics:

| Question | What the policy says |
|---|---|
| Who owns inventions? | IP made at AIIMS by faculty, project and supporting staff or visitors vests in AIIMS, whether or not intramural funds were used; for students, IP made using AIIMS resources |
| Sponsored research | A written agreement with the sponsor governs; without one, AIIMS owns the IP |
| Joint inventions | Jointly owned, with shares based on intellectual input |
| Who manages licensing? | The Intellectual Property Rights and Technology Transfer (IPR and TT) Division |
| Who approves agreements? | The Intellectual Property Management Committee (IPMC), chaired by the Dean (Research), the authorised signatory |
| Revenue sharing | Inventors 70%, institute 30%, of revenue after direct commercialisation costs such as patenting are recovered |
| Failure to commercialise | If not commercialised within two years of licence or transfer, AIIMS may transfer the know-how to a third party |
| Disputes and courts | Disputes between the division and inventors go to the Director, whose decision is final; disputes with partners follow the agreement; Delhi courts have jurisdiction |

AIIMS describes the IPR and TT Division as growing out of the Patent Cell set up in 2000, managed by the IPR Management Committee under the Dean (Research). Its [research section pages](https://research.aiims.edu/?p=263) list it alongside the Centre for Medical Innovation and Entrepreneurship (CMIE), a bio-incubator under BIRAC's BioNEST scheme.

A 70% inventor share is high by Indian standards, and it matters to you as a licensee. An inventing clinician has a strong personal interest in the deal and is usually a strong ally inside the institute.

## How do you approach AIIMS?

Because there is no standing catalogue, approach through the technology or the person.

1. Identify the technology. Patent searches on IP India for AIIMS as applicant, published papers by AIIMS departments and conference talks are the usual leads.
2. Contact the inventor and the IPR and TT Division together. Going only to the doctor delays things, because the policy routes every agreement through the division and IPMC.
3. Sign an NDA. The policy requires an NDA or a material transfer agreement before AIIMS or its inventors share confidential information or research material.
4. Send a short proposal: your company, the product you would build, your regulatory and manufacturing capacity, and the terms you have in mind.
5. Negotiate the term sheet with the division, then the full agreement for IPMC approval.

Two recent examples show the range. In 2019, [BCIL licensed a CPR device](https://biotech.co.in/en/bcil-licensed-cardiopulmonary-resuscitation-device-technology-to-ms-rcupelifesciences-pvt-ltd-1) developed under the School of International Biodesign, a programme run at AIIMS New Delhi and IIT Delhi, to a Bengaluru startup; BCIL manages that programme's IP and technology transfer for DBT. In September 2026, [AIIMS New Delhi and BPL Medical Technologies formalised the transfer](https://biospectrumindia.com/news/16/28508/bpl-medical-technologies-and-aiims-delhi-partner-to-take-forward-ai-powered-mammography-technology.html) of an AI mammography technology developed at AIIMS. Neither announcement disclosed financial terms.

One lesson follows from the first example: if the invention came out of a joint programme, find out who actually manages the IP before you negotiate.

**Licensing an AIIMS technology**
1. Find the invention: Patents, papers, the inventing clinician
2. Contact the IPR and TT Division: Together with the inventor
3. Sign an NDA: Required before confidential data is shared
4. Term sheet: Fee, royalty, field, milestones
5. IPMC approval and signature: Dean (Research) signs

## What does an AIIMS licence look like?

AIIMS's policy allows a technology transfer fee, royalties or other benefit sharing, set in each executed agreement. It does not fix amounts or say whether licences are exclusive. Points worth putting on the table:

- Field and territory. A device may have uses in several specialties; license the field you will actually develop.
- Diligence. The two-year commercialisation clause in the policy is short for a Class C device that needs clinical investigation. Agree milestones you can meet, such as a test licence application or first clinical site, rather than a launch date.
- Clinical access. Ask whether AIIMS departments will take part in validation or clinical studies, and on what terms. This is often worth more than the patent.
- Sponsored work. If you also fund further development, the sponsorship agreement decides who owns improvements. Sponsors get first rights to commercialise only where the agreement says so in advance.
- Conflicts of interest. The policy requires inventors to disclose interests, including family stakes in a licensee, and licensing to such a company needs the division's approval. Disclose early if a founder is related to an inventor.
- Jurisdiction. Agreements fall under Delhi courts. Plan dispute resolution in the agreement accordingly.

**Illustration with invented figures.** A Hyderabad device company licenses a patented surgical accessory from AIIMS non-exclusively for India.

| Item | Amount |
|---|---|
| Technology transfer fee at signing | ₹10,00,000 |
| Royalty | 4% of net sales |
| Net sales in year three (8,000 units at ₹3,500) | ₹2,80,00,000 |
| Royalty in year three | ₹11,20,000 |
| Inventors' share (70%), before cost recovery | ₹7,84,000 |
| AIIMS's share (30%), before cost recovery | ₹3,36,000 |

Direct costs such as patenting are recovered first, so the actual shares would be smaller. Your payment does not change with the split. It shows why the inventing doctor cares about your sales figures, and why a good relationship with them matters after signing.

## What regulatory work follows?

A licence gives you the right to use the IP and know-how. Making and selling a medical device needs a licence under the Medical Devices Rules, 2017: most Class A and B devices from the State Licensing Authority, Class C and D from CDSCO, usually after a test licence. A drug or biological product follows the drug rules, and diagnostics have their own pathway. Our guide to [licensing a medical device from SCTIMST](https://zernyxhub.com/blog/license-technology-from-sctimst) sets out the CDSCO forms step by step, and the same sequence applies to a device from AIIMS.

Check the device class before you agree fees. Its class decides the regulator, the evidence you need and how long revenue will take to arrive.

## How do other medical institutes compare?

| Institute or body | How technologies are offered | Where to read more |
|---|---|---|
| AIIMS New Delhi | Through the IPR and TT Division; no standing catalogue | AIIMS IPR Policy 2017 |
| SCTIMST, Thiruvananthapuram | Expression of Interest calls with annexures, signed hard copy | [SCTIMST guide](https://zernyxhub.com/blog/license-technology-from-sctimst) |
| ICMR institutes | ICMR's own IP guidelines and technology transfer calls | [ICMR guide](https://zernyxhub.com/blog/license-technology-from-icmr) |
| Other AIIMS, PGIMER, JIPMER and medical colleges | Each follows its own IP policy, where one exists | The institute's research or IPR office |

Treat each institute as separate. Newer AIIMS campuses are autonomous institutes, and you should not assume the New Delhi policy applies to them without checking.

**Two ways medical institutes offer technologies**
Open call (SCTIMST style):
- Listed technologies and deadlines
- Formal annexures
- Shortlisting before talks
Approach-led (AIIMS style):
- No standing catalogue
- Start with the inventor and the division
- Terms built case by case
Either way, the institute's IP policy sets the rules.

## Common mistakes

- Negotiating only with the doctor. Under the policy, the IPR and TT Division and IPMC handle agreements.
- Skipping the NDA because the clinician is happy to talk. The policy requires one before confidential information is shared.
- Agreeing a two-year launch date for a product that needs clinical investigation.
- Assuming an invention from a joint programme belongs to AIIMS alone.
- Checking the patent only by title. Confirm the status of each application on IP India; [patent due diligence](https://zernyxhub.com/blog/patent-due-diligence) lists what to look at.

My view: medical institutes are an underused source of products for Indian device and diagnostics firms, because the inventors are also the first users. I cannot tell you typical AIIMS fees or how long approval takes, because the institute does not publish them; ask the IPR and TT Division at the first meeting.

For the wider process of licensing from Indian institutes, see [licensing technology from Indian institutions](https://zernyxhub.com/blog/license-technology-from-indian-institutions). To compare medical technologies on offer across many institutes, [Zernyx Hub](https://www.zernyxhub.com) has mapped patents from universities across India, with AI business insight on each.

## Common questions

### Who owns inventions made at AIIMS?

Under the AIIMS IPR Policy 2017, IP made at AIIMS by faculty, staff or visitors vests in AIIMS, whether or not intramural funds were used, and so does IP students make using AIIMS resources. Where a sponsor funded the work under a written agreement, that agreement governs. Jointly made inventions are jointly owned, in shares based on intellectual input.

### Who do I contact to license an AIIMS technology?

The Intellectual Property Rights and Technology Transfer Division of AIIMS New Delhi, which grew out of the Patent Cell set up in 2000. It works under the Intellectual Property Management Committee, chaired by the Dean (Research), who is the authorised signatory under the policy.

### Can AIIMS take a technology back if I do not commercialise it?

The policy says that if a licensee does not commercialise within two years of the licence or transfer, AIIMS may transfer the know-how to a third party. Expect diligence milestones in the agreement, and negotiate realistic ones for a regulated product.

### Do other medical institutes license technologies the same way?

Each institute follows its own IP policy. SCTIMST in Thiruvananthapuram uses Expression of Interest calls, and ICMR has its own guidelines for technologies from its institutes. Read the policy of the institute you are dealing with, because ownership, revenue sharing and approval rules differ.

---

Published by Zernyx Hub. More: https://zernyxhub.com/llms.txt
